Description: A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers
Target Patient Population: Melanoma, Ovarian, Non Small Cell Lung Cancer, Colorectal and Pancreatic cancers
Study Design: Drug is given IV weekly.